DK2931042T3 - Anthracyclinformuleringer - Google Patents
Anthracyclinformuleringer Download PDFInfo
- Publication number
- DK2931042T3 DK2931042T3 DK13863251.8T DK13863251T DK2931042T3 DK 2931042 T3 DK2931042 T3 DK 2931042T3 DK 13863251 T DK13863251 T DK 13863251T DK 2931042 T3 DK2931042 T3 DK 2931042T3
- Authority
- DK
- Denmark
- Prior art keywords
- anthracycline
- formulations
- anthracycline formulations
- Prior art date
Links
- 229940045799 anthracyclines and related substance Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737003P | 2012-12-13 | 2012-12-13 | |
| PCT/US2013/075002 WO2014093815A1 (en) | 2012-12-13 | 2013-12-13 | Anthracycline formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2931042T3 true DK2931042T3 (da) | 2021-06-07 |
Family
ID=50934989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13863251.8T DK2931042T3 (da) | 2012-12-13 | 2013-12-13 | Anthracyclinformuleringer |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20150342975A1 (https=) |
| EP (2) | EP3915369A1 (https=) |
| JP (5) | JP6433913B2 (https=) |
| AU (1) | AU2013359048A1 (https=) |
| CA (1) | CA2894548C (https=) |
| DK (1) | DK2931042T3 (https=) |
| WO (1) | WO2014093815A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3915369A1 (en) * | 2012-12-13 | 2021-12-01 | CytRx Corporation | Anthracycline formulations |
| CN113842392A (zh) * | 2013-06-05 | 2021-12-28 | 西特克斯公司 | 用于治疗癌症的细胞毒素剂 |
| US11393557B2 (en) | 2015-08-25 | 2022-07-19 | Nantomics, Llc | Systems and methods for high-accuracy variant calling |
| US11071812B2 (en) * | 2016-05-31 | 2021-07-27 | Penumbra, Inc. | Methods and apparatus for extracting doxorubicin from blood and measuring doxorubicin in blood |
| EP3668538A4 (en) | 2017-08-15 | 2021-06-16 | NantCell, Inc. | HANK-CETUXIMAB COMBINATIONS AND PROCEDURES |
| WO2020081174A1 (en) | 2018-10-16 | 2020-04-23 | Nant Holdings Ip, Llc | Alpha emitter compositions and methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8426672D0 (en) | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| JP2915252B2 (ja) | 1993-06-30 | 1999-07-05 | 明治製菓株式会社 | 溶解性が改善された製剤の製造法 |
| EP0954283B1 (en) * | 1996-12-30 | 2007-03-21 | Battelle Memorial Institute | Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation |
| DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
| DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
| JP2004536026A (ja) * | 2000-11-28 | 2004-12-02 | トランスフォーム ファーマシューティカルズ，インコーポレーティッド． | パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤 |
| US20050148534A1 (en) * | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| JP5634862B2 (ja) * | 2007-05-16 | 2014-12-03 | カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低粘度アントラサイクリン製剤 |
| EP2216049A1 (en) * | 2009-02-06 | 2010-08-11 | Freie Universität Berlin | Drug conjugates with polyglycerols |
| MX2011004019A (es) * | 2008-10-15 | 2011-06-24 | Angiochem Inc | Conjugados de etoposido y doxorubicina para entrega de farmacos. |
| EP3915369A1 (en) * | 2012-12-13 | 2021-12-01 | CytRx Corporation | Anthracycline formulations |
-
2013
- 2013-12-13 EP EP21169873.3A patent/EP3915369A1/en active Pending
- 2013-12-13 EP EP13863251.8A patent/EP2931042B1/en active Active
- 2013-12-13 CA CA2894548A patent/CA2894548C/en active Active
- 2013-12-13 JP JP2015547985A patent/JP6433913B2/ja active Active
- 2013-12-13 WO PCT/US2013/075002 patent/WO2014093815A1/en not_active Ceased
- 2013-12-13 DK DK13863251.8T patent/DK2931042T3/da active
- 2013-12-13 AU AU2013359048A patent/AU2013359048A1/en not_active Abandoned
- 2013-12-13 US US14/651,898 patent/US20150342975A1/en not_active Abandoned
-
2017
- 2017-05-09 US US15/590,331 patent/US10328093B2/en active Active
-
2018
- 2018-08-01 JP JP2018145172A patent/JP6833768B2/ja active Active
-
2019
- 2019-08-09 JP JP2019147584A patent/JP2019206583A/ja not_active Withdrawn
-
2021
- 2021-05-21 JP JP2021085891A patent/JP7213303B2/ja active Active
- 2021-05-21 JP JP2021085892A patent/JP2021120415A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3915369A1 (en) | 2021-12-01 |
| CA2894548C (en) | 2021-01-12 |
| JP7213303B2 (ja) | 2023-01-26 |
| EP2931042A4 (en) | 2016-06-01 |
| US20150342975A1 (en) | 2015-12-03 |
| JP6433913B2 (ja) | 2018-12-05 |
| JP2018165280A (ja) | 2018-10-25 |
| EP2931042B1 (en) | 2021-04-28 |
| WO2014093815A1 (en) | 2014-06-19 |
| US10328093B2 (en) | 2019-06-25 |
| US20170340655A1 (en) | 2017-11-30 |
| CA2894548A1 (en) | 2014-06-19 |
| JP2021120414A (ja) | 2021-08-19 |
| JP2019206583A (ja) | 2019-12-05 |
| JP2021120415A (ja) | 2021-08-19 |
| AU2013359048A1 (en) | 2015-07-02 |
| JP2016503026A (ja) | 2016-02-01 |
| JP6833768B2 (ja) | 2021-02-24 |
| EP2931042A1 (en) | 2015-10-21 |
| HK1209973A1 (en) | 2016-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR23C1020I2 (fr) | Conjugues pyrrolobenzodiazepine-anticorps | |
| HRP20211423T4 (hr) | Formulacije enzalutamida | |
| DK2906251T3 (da) | Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater | |
| BR112015008232A2 (pt) | conjugados pirrolbenzodiazepina-anticorpo | |
| EP2841103A4 (en) | DR5 Ligand-drug conjugates | |
| DK3117837T3 (da) | Antistofformuleringer | |
| DK2920304T3 (da) | Oligonukleotidkonjugater | |
| CO6801645A2 (es) | Nuevos inmunoconjugados | |
| EP3065716C0 (en) | FORMULATIONS | |
| EP2907824A4 (en) | ANTIBODY-drug conjugate | |
| DK2825087T3 (da) | Otoscanner | |
| DK2839013T3 (da) | Ikke-disruptiv-gen-targetering | |
| DE112012006109A5 (de) | Okklusionsschienenanordnung | |
| EP2846781A4 (en) | PROLIPOSOMAL TESTOSTERONE FORMULATIONS | |
| BR112014032798A2 (pt) | composição | |
| PT2928489T (pt) | Composição imunogénica | |
| EP2880400A4 (en) | INCLINATION INDICATOR | |
| ME03413B (me) | Kompozicije које sadrže peg i askorbat | |
| EP2877026A4 (en) | Clomazone FORMULATIONS | |
| DK2825157T3 (da) | Aminosyrelipider | |
| HRP20171889T1 (hr) | Formulacije kombinacije darunavira | |
| EP2880250A4 (en) | Remote activated deflector | |
| EP2860233A4 (en) | PUNCTURE CLOSURE MEANS | |
| DE112012006214T8 (de) | Wulstringwickler | |
| DK2831122T3 (da) | Anthocyanidin-kompleks |